The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women

Purpose Laquinimod is an orally dosed immuno-modulator currently under development for Huntington’s disease (HD). Preclinical findings suggest potential teratogenicity of laquinimod, thus the reproductive ability of females with HD treated with laquinimod needs to be closely managed. Because combine...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of clinical pharmacology 2019-01, Vol.75 (1), p.41-49
Hauptverfasser:	Elgart, Anna, Zur, Arik A., Mimrod, Dorit, Dror, Vered, Bar-Ilan, Oren, Korver, Tjeerd, Spiegelstein, Ofer
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adolescent Adult Area Under Curve Bioequivalence Biomedical and Life Sciences Biomedicine Contraceptives Contraceptives, Oral, Combined - administration & dosage Contraceptives, Oral, Combined - adverse effects Contraceptives, Oral, Combined - pharmacokinetics Cross-Over Studies Crossovers Double-Blind Method Drug dosages Drug interaction Drug Interactions Ethinyl Estradiol - administration & dosage Ethinyl Estradiol - adverse effects Ethinyl Estradiol - pharmacokinetics Ethinylestradiol Female Females Headache Headache - chemically induced Headache - epidemiology Humans Huntington's disease Huntingtons disease Immunologic Factors - administration & dosage Immunologic Factors - adverse effects Immunologic Factors - pharmacology Levonorgestrel - administration & dosage Levonorgestrel - adverse effects Levonorgestrel - pharmacokinetics Oral contraceptives Pharmacokinetics Pharmacokinetics and Disposition Pharmacology/Toxicology Quinolones - administration & dosage Quinolones - adverse effects Quinolones - pharmacology Teratogenicity Therapeutic Equivalency Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!